BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Healionics Corporation Awarded $900k Grant from National Institutes of Health (NIH)


9/20/2012 11:04:11 AM

SEATTLE, Sept. 20, 2012 /PRNewswire/ -- Healionics Corporation received a $909,165 Phase II Small Business Innovation Research (SBIR) grant award from the National Institute of General Medical Sciences division of the National Institutes of Health (NIH) for preclinical studies to advance STARcuffTM, a STAR® Biomaterial-based anti-infective exit site sleeve for hemodialysis catheters. Andrew Marshall, Healionics' Chief Technology Officer, is the Principal Investigator for this research project.

(Logo: http://photos.prnewswire.com/prnh/20120920/SF77922LOGO)

Titled, "Anti-Infective Dermal Integration Sleeves for Needle-Free Dialysis Access Devices," the award provides funding to refine the STARcuff anti-infection technology and broaden its range of device applicability.

Hemodialysis patients are at high risk for life-threatening bloodstream infections. Treatment of catheter-associated infections at $35,000 to $60,000 per episode exceeds the yearly cost of routine dialysis sessions. Nearly half of these infections proceed extraluminally via the exit site.

"Catheters loaded with active antimicrobial agents or antiseptics are a controversial option for chronic dialysis patients due to the serious threat of microbial resistance," says Marshall. "STARcuff is an attractive approach because it can potentially provide long-term protection against infection without any active agents."

More information about SBIR grants from the National Institutes of Health can be found at http://grants.nih.gov/grants/funding/sbir.htm.

About Healionics Corporation
Healionics develops and manufactures STAR® Biomaterials for implanted medical devices. The precisely controlled pore structure of the innovative STAR technology induces a favorable integrated healing response, overcoming fibrotic reactions and infection issues to enhance medical device performance and longevity. The company has two medical device subsidiaries: iSTAR Medical and qSTAR Medical.

Websites:
www.healionics.com
www.istarmed.com
www.qstarmed.com

SOURCE Healionics Corporation



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES